NCT06648096View on ClinicalTrials.gov

Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Fanconi AnemiaHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Afatinib

Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Medizinische Hochschule Hannover, Hanover

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors
All Listed Sponsors
collaborator

MFAR Clinical Research S.L.

UNKNOWN

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT06648096 - Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Biotech Hunter | Biotech Hunter